구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Irinotecan Hydrochloride (Irinotecan Hydrochloride) Janssen Research & Development, LL…·Advanced Malignant Solid Neoplasm 149 trials·t½ 12 h |
|---|---|
Overview Program | Irinotecan Hydrochloride |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Advanced Malignant Solid Neoplasm |
Overview Indication | Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8 |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting VEGF have demonstrated clinical benefit, their efficacy is frequently limited by adaptive resistance, systemic toxicity, and incomplete suppression of VEGF signaling |
MoA Biomarker | biomarkers for diagnosis, drug resistance, sensitivity and prognosis |
PK/PD Half-life | 12 h |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Irinotecan Hydrochloride Administration Considering Dosing-Time Attenuates Delayed Diarrhea in Rats.. Background: Irinotecan hydrochloride (CPT-11) is an important anticancer drug used in a wide range of regimens to treat colorectal and gastric cancers, and one of its severe side effects is delayed diarrhea. Therefore, based on known circadian variations in intestinal function and drug metabolism,… |
Clinical Safety signal | Irinotecan Hydrochloride Administration Considering Dosing-Time Attenuates Delayed Diarrhea in Rats.. Background: Irinotecan hydrochloride (CPT-11) is an important anticancer drug used in a wide range of regimens to treat colorectal and gastric cancers, and one of its severe side effects is delayed diarrhea. Therefore, based on known circadian variations in intestinal function and drug metabolism,… |
Clinical Selected reported efficacy | ORR 90% |
Clinical Reported ORR | 90% |
Clinical Result source | ClinicalTrials.gov NCT00393094 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00393094 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Irinotecan Hydrochloride (Irinotecan Hydrochloride) Janssen Research & Development, LL…·Advanced Malignant Solid Neoplasm 149 trials·t½ 12 h |
|---|---|
Overview Program | Irinotecan Hydrochloride |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Advanced Malignant Solid Neoplasm |
Overview Indication | Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8 |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting VEGF have demonstrated clinical benefit, their efficacy is frequently limited by adaptive resistance, systemic toxicity, and incomplete suppression of VEGF signaling |
MoA Biomarker | biomarkers for diagnosis, drug resistance, sensitivity and prognosis |
PK/PD Half-life | 12 h |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Irinotecan Hydrochloride Administration Considering Dosing-Time Attenuates Delayed Diarrhea in Rats.. Background: Irinotecan hydrochloride (CPT-11) is an important anticancer drug used in a wide range of regimens to treat colorectal and gastric cancers, and one of its severe side effects is delayed diarrhea. Therefore, based on known circadian variations in intestinal function and drug metabolism,… |
Clinical Safety signal | Irinotecan Hydrochloride Administration Considering Dosing-Time Attenuates Delayed Diarrhea in Rats.. Background: Irinotecan hydrochloride (CPT-11) is an important anticancer drug used in a wide range of regimens to treat colorectal and gastric cancers, and one of its severe side effects is delayed diarrhea. Therefore, based on known circadian variations in intestinal function and drug metabolism,… |
Clinical Selected reported efficacy | ORR 90% |
Clinical Reported ORR | 90% |
Clinical Result source | ClinicalTrials.gov NCT00393094 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00393094 |
추천 비교
추천 비교